Mail

CTMX - CytomX Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

10.40

+0.17 (+1.66%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	10.23
Open	10.19
Bid	0.00 x 1100
Ask	12.46 x 3000
Day's Range	10.10 - 10.54
52 Week Range	8.94 - 27.20
Volume	300,960
Avg. Volume	399,711

Market Cap	471.24M
Beta (3Y Monthly)	0.42
PE Ratio (TTM)	N/A
EPS (TTM)	-1.92
Earnings Date	Nov 5, 2018 - Nov 9, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	21.45

Trade prices are not sourced from all markets

All

News

Press Releases

GlobeNewswire16 days ago
CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting
- Monotherapy Expansion Cohorts Show Clinical Activity Across Multiple Cancer Types - - Differentiated Safety Profile Continues to Emerge - SOUTH SAN FRANCISCO, Calif.,.
GlobeNewswire20 days ago
CytomX Therapeutics to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., May 28, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
Thomson Reuters StreetEvents26 days ago
Edited Transcript of CTMX earnings conference call or presentation 9-May-19 9:00pm GMT
Q1 2019 CytomX Therapeutics Inc Earnings Call
GlobeNewswirelast month
CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 15, 2019 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
Motley Foollast month
CytomX Therapeutics, Inc. (CTMX) Q1 2019 Earnings Call Transcript
CTMX earnings call for the period ending March 31, 2019.
Insider Monkeylast month
Were Hedge Funds Right About Dumping CytomX Therapeutics, Inc. (CTMX)?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
Zackslast month
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 41.51% and 116.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Associated Presslast month
CytomX Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 31 cents. The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by ...
GlobeNewswirelast month
CytomX Therapeutics Announces First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
Thomson Reuters StreetEventslast month
Edited Transcript of CTMX earnings conference call or presentation 6-Nov-18 10:00pm GMT
Q3 2018 CytomX Therapeutics Inc Earnings Call
GlobeNewswirelast month
CytomX Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
GlobeNewswire2 months ago
CytomX Therapeutics to Announce First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., May 02, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
Zacks2 months ago
Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MoneyShow2 months ago
Long-Term "GameChangers" in Biotech
When I'm hunting for unicorns, I start with biotech. They won't all be winners. But in a well-constructed portfolio, enough of them will hit their commercial targets with sufficient force to make their shareholders very happy, explains Hilary Kramer, editor of GameChangers.
GlobeNewswire2 months ago
CytomX Therapeutics Appoints Elaine V. Jones, Ph.D., to Board of Directors
CytomX Therapeutics, Inc. (CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that Elaine V. Jones, Ph.D., has joined the company’s board of directors effective May 1, 2019. Dr. Jones brings to CytomX significant experience in pharmaceutical drug discovery and business development as well as more than 19 years of investment experience, which included previously serving on the CytomX board from December 2014 to December 2016 after leading its Series C financing round in 2014. Dr. Jones will be retiring in late April from her current role as vice president, worldwide business development and senior partner at Pfizer Ventures, the venture capital arm of Pfizer Inc. Since joining Pfizer Ventures as executive director in 2008, Dr. Jones was responsible for making and managing venture investments for Pfizer as well as serving in Board roles for several biotechnology platform and therapeutic companies. Prior to this, Dr. Jones held the position of general partner at EuclidSR Partners, a venture firm specializing in private investment in public equity within the health sciences, healthcare, biopharmaceutical sectors.
Simply Wall St.2 months ago
What Kind Of Investor Owns Most Of CytomX Therapeutics, Inc. (NASDAQ:CTMX)?
A look at the shareholders of CytomX Therapeutics, Inc. (NASDAQ:CTMX) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of s...
GuruFocus.com2 months ago
Consider These 3 Falling Knives
Wall Street issued a buy recommendation rating for all three stocks, increasing the likelihood of them outperforming the S&P 500 Index over the next 52 weeks. Warning! GuruFocus has detected 2 Warning Sign with CTMX. Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives.
GlobeNewswire2 months ago
AACR 2019 Presentations Highlight CX-2009, a First-In-Class Probody Drug Conjugate Targeting Novel Tumor Antigen, CD166
- PROCLAIM-CX-2009 Dose Escalation Study Demonstrates Anti-Tumor Activity in Multiple Tumor Types - - Preclinical Studies Suggest Role of CD166 Expression Level in Anti-Cancer.
Benzinga3 months ago
The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...
GlobeNewswire3 months ago
CytomX Therapeutics Announces Transition of Chief Financial Officer
CytomX Therapeutics, Inc. (CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that its Chief Financial Officer, Debanjan Ray, will be stepping down from the Company, effective May 15, 2019, to become the Chief Executive Officer of a newly-formed private biotechnology company. CytomX is initiating the search for Mr. Ray‘s successor. Mr. Ray will continue to be available as an advisor to the Company after his departure.
Simply Wall St.3 months ago
Have Insiders Been Buying CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mentionRead More...
GlobeNewswire3 months ago
CytomX to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., March 05, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
Thomson Reuters StreetEvents3 months ago
Edited Transcript of CTMX earnings conference call or presentation 27-Feb-19 10:00pm GMT
Full Year 2018 CytomX Therapeutics Inc Earnings Call
GlobeNewswire4 months ago
CytomX Therapeutics Announces Presentations at the American Association for Cancer Research Annual Meeting 2019
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
GlobeNewswire4 months ago
CytomX Therapeutics Announces Full-Year 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.